Bluejay Diagnostics Gains Pre-Market on U.S. Manufacturing Agreement
Bluejay Diagnostics (BJDX) soared up to 213% in premarket trading after announcing a U.S. manufacturing deal with Argonaut for its Symphony test system, but shares remain volatile as Symphony still awaits FDA clearance, clinical enrollment is incomplete, and Bluejay warns it will need more funding within a year or may face liquidation if capital can’t be raised.